+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gamma-aminobutyric Acid Receptor Agonist Market - Global Forecast 2026-2032- Product Image
Gamma-aminobutyric Acid Receptor Agonist Market - Global Forecast 2026-2032- Product Image
Sale

Gamma-aminobutyric Acid Receptor Agonist Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6151827
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gamma-aminobutyric Acid Receptor Agonist Market is projected to reach USD 2.39 Billion in 2026. It is expected to continue growing at a CAGR of 5.92%, reaching USD 3.37 Billion by 2032.

Introduction to Gamma-Aminobutyric Acid Receptor Agonists

Gamma-aminobutyric acid receptor agonists are pharmacological agents that enhance signaling through inhibitory gamma-aminobutyric acid pathways, particularly receptors associated with neuronal excitability, muscle tone, sleep, anxiety, and seizure control. Their clinical use spans multiple therapeutic areas, but benefits must be balanced against sedation, tolerance, dependence, respiratory depression, interactions, and withdrawal risks. Product evaluation therefore depends on receptor selectivity, route of administration, duration of action, patient characteristics, and the quality of safety monitoring.

Safety, Precision, and Access Are Reshaping the Landscape

The landscape is shifting toward more precise treatment selection, stronger controls around dependence and misuse, and closer monitoring of central-nervous-system adverse effects. Regulators and clinicians increasingly emphasize appropriate indication, limited exposure where risks are material, medication reconciliation, and non-pharmacological alternatives. Advances in formulation design and clinical stratification may support more targeted use, while reimbursement conditions, prescribing rules, controlled-substance requirements, and shortages can affect access across health systems.

Artificial Intelligence Is Strengthening Discovery and Clinical Oversight

Artificial intelligence can assist receptor modeling, compound screening, pharmacovigilance, clinical-trial recruitment, and identification of patients at elevated risk of sedation, falls, respiratory complications, or problematic use. Its value depends on representative datasets, transparent validation, clinically meaningful endpoints, and careful governance of privacy and bias. AI should support-not replace-pharmacological expertise, informed consent, regulatory review, and clinician judgment, particularly when treatment decisions involve dependence or withdrawal risk.

Regional Insights Span Mature Regulation and Uneven Access

North America combines advanced research capacity with stringent oversight of controlled medicines and substantial attention to misuse, overdose, and prescribing quality. Europe emphasizes harmonized safety assessment, pharmacovigilance, and evidence-based prescribing across diverse national systems. Asia-Pacific includes major research and manufacturing capabilities alongside wide variation in regulatory maturity and healthcare access. Latin America faces differences in availability, affordability, and enforcement, while local clinical needs remain important. The Middle East is shaped by expanding specialist care, national medicines policies, and controlled-drug governance. Africa presents significant opportunities for improved diagnosis and access, but supply reliability, specialist capacity, and monitoring infrastructure remain central considerations.

Economic and Security Groups Influence Regulation and Supply Resilience

ASEAN markets differ in regulatory alignment, healthcare financing, and access to specialist treatment, making regional cooperation relevant for quality standards and pharmacovigilance. BRICS members combine large and varied patient populations with differing approval pathways, domestic production capabilities, and controlled-medicine policies. The European Union benefits from coordinated scientific and safety frameworks while retaining national differences in reimbursement and clinical practice. G7 members generally possess strong regulatory and research infrastructures, with continued focus on opioid-sparing care, misuse prevention, and supply continuity. GCC states are strengthening healthcare capacity and regulatory coordination, while NATO members span mature and emerging systems where medicine security, emergency preparedness, and harmonized clinical safeguards are important.

Country Insights Highlight Diverse Clinical and Regulatory Priorities

Australia and Canada maintain structured regulatory systems and emphasize responsible prescribing, monitoring, and access across geographically dispersed populations. Brazil and Mexico must balance clinical need with affordability, supply continuity, and controls for medicines with misuse potential. China and India combine substantial pharmaceutical and healthcare capabilities with evolving regulatory oversight and varied access between urban and rural settings. Japan and South Korea prioritize aging-related care, safety, and medication management. France, Germany, Italy, Spain, and the United Kingdom operate within mature European frameworks, while differing in reimbursement, prescribing guidance, and health-system organization. Russia’s environment reflects national regulatory priorities, domestic supply considerations, and variable access to specialist services. In the United States, controlled-substance oversight, prescribing quality, pharmacovigilance, and disparities in access remain prominent concerns.

Industry Leaders Should Pair Innovation With Rigorous Risk Management

Leaders should prioritize receptor-selective and clinically differentiated approaches that address defined unmet needs without weakening safety safeguards. Evidence plans should measure functional outcomes, dependence and withdrawal risk, respiratory and cognitive effects, interactions, and outcomes in older or medically complex patients. Organizations should strengthen real-world safety surveillance, clinician education, patient counseling, secure distribution, and responsible discontinuation protocols. Regional strategies should be adapted to local regulation, reimbursement, supply conditions, and healthcare capacity. Partnerships with regulators, health systems, and patient groups can improve evidence quality, appropriate use, and trust.

Research Methodology for the Executive Summary

This summary uses a structured qualitative assessment of gamma-aminobutyric acid receptor agonists, examining pharmacology, therapeutic applications, safety considerations, regulation, access, technology adoption, and health-system conditions. The geographic framework covers North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, with additional comparison across ASEAN, BRICS, the European Union, G7, GCC, and NATO. Country-level interpretation includes Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom, and the United States. Findings are framed as evidence-informed strategic themes and intentionally exclude market estimates, market sizing, market shares, forecasts, and company-specific analysis.

Conclusion: Responsible Precision Will Define Future Use

Gamma-aminobutyric acid receptor agonists remain clinically relevant because modulation of inhibitory neurotransmission can address important neurological and psychiatric needs. Their future role will depend less on broad utilization than on precise patient selection, safer treatment pathways, accountable prescribing, resilient supply, and credible post-use monitoring. Advances in data science and pharmacology may improve decision-making, but durable progress requires regulatory discipline, transparent evidence, and health-system capacity across regions and country groups.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gamma-aminobutyric Acid Receptor Agonist Market, by Product Type
7.1. Introduction
7.2. Barbiturate
7.2.1. Long Acting
7.2.2. Short Acting
7.2.3. Ultra Short Acting
7.3. Benzodiazepine
7.3.1. Intermediate Acting
7.3.2. Long Acting
7.3.3. Short Acting
7.4. Propylene Glycol Derivatives
8. Gamma-aminobutyric Acid Receptor Agonist Market, by Form
8.1. Introduction
8.2. Capsule
8.3. Injectable Solution
8.4. Oral Solution
8.5. Powder For Reconstitution
8.6. Tablet
9. Gamma-aminobutyric Acid Receptor Agonist Market, by Administration Route
9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.4. Oral
9.5. Subcutaneous
10. Gamma-aminobutyric Acid Receptor Agonist Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Gamma-aminobutyric Acid Receptor Agonist Market, by Indication
11.1. Introduction
11.2. Anxiety Disorders
11.3. Epilepsy
11.4. Insomnia
11.5. Muscle Spasms
12. Gamma-aminobutyric Acid Receptor Agonist Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.3.1. Pharmacy Specific Platforms
12.3.2. Third Party Sellers
12.4. Retail Pharmacy
12.4.1. Chain
12.4.2. Independent
13. Gamma-aminobutyric Acid Receptor Agonist Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Gamma-aminobutyric Acid Receptor Agonist Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Gamma-aminobutyric Acid Receptor Agonist Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Cipla Limited
17.2. Dr. Reddy's Laboratories Limited
17.3. Hikma Pharmaceuticals PLC
17.4. Jazz Pharmaceuticals plc
17.5. Lupin Limited
17.6. Pfizer Inc.
17.7. Sandoz International GmbH
17.8. Sun Pharmaceutical Industries Limited
17.9. Teva Pharmaceutical Industries Ltd.
17.10. Viatris Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Gamma-aminobutyric Acid Receptor Agonist Market, Years Considered for the Study
FIGURE 2. Global Gamma-aminobutyric Acid Receptor Agonist Market, Research Design
FIGURE 3. Global Gamma-aminobutyric Acid Receptor Agonist Market, Research Framework
FIGURE 4. Global Gamma-aminobutyric Acid Receptor Agonist Market, Data Triangulation
FIGURE 5. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2025 vs 2032 (%)
FIGURE 9. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 11. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 15. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Gamma-aminobutyric Acid Receptor Agonist Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Gamma-aminobutyric Acid Receptor Agonist Market Segmentation & Coverage
TABLE 2. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, 2017-2032 (USD Million)
TABLE 3. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Barbiturate Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Barbiturate Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Barbiturate Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Long Acting Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Long Acting Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Long Acting Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Short Acting Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Short Acting Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Short Acting Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ultra Short Acting Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ultra Short Acting Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ultra Short Acting Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Benzodiazepine Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Benzodiazepine Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Benzodiazepine Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Intermediate Acting Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Intermediate Acting Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Intermediate Acting Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Long Acting Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Long Acting Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Long Acting Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Short Acting Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Short Acting Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Short Acting Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Propylene Glycol Derivatives Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Propylene Glycol Derivatives Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Propylene Glycol Derivatives Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 32. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Injectable Solution Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Injectable Solution Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Injectable Solution Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Oral Solution Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Oral Solution Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Oral Solution Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Powder For Reconstitution Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Powder For Reconstitution Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Powder For Reconstitution Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 48. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 61. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 71. Global Anxiety Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Anxiety Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Anxiety Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Epilepsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Epilepsy Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Epilepsy Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Insomnia Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Insomnia Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Insomnia Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Muscle Spasms Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Muscle Spasms Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Muscle Spasms Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Pharmacy Specific Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Pharmacy Specific Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Pharmacy Specific Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Third Party Sellers Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Third Party Sellers Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Third Party Sellers Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Chain Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Chain Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Chain Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Independent Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Independent Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Independent Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 117. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 119. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 120. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 121. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 122. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 123. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 124. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 125. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 127. North America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 128. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 130. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 131. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 132. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 133. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 134. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 135. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 136. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 138. Latin America Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 139. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 141. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 142. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 143. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 144. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 145. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 146. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 149. Europe Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 150. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 152. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 153. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 154. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 155. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 156. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 157. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 160. Middle East Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 161. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 163. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 164. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 165. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 166. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 167. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 168. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 169. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 171. Africa Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 172. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 173. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 174. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 175. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 176. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 177. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 178. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 179. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 180. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 181. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 183. ASEAN Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 184. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 186. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 187. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 188. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 189. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 190. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 191. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 192. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 193. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 194. GCC Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 195. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 196. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 197. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 198. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 199. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 200. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 201. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 202. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 203. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 205. European Union Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 206. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 208. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 209. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 210. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 211. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 212. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 213. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 214. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 216. BRICS Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 217. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 218. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 219. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 220. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 221. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 222. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 223. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 224. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 225. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 227. G7 Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 228. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 229. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 230. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 231. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 232. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 233. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 234. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 235. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 236. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 238. NATO Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 239. Global Gamma-aminobutyric Acid Receptor Agonist Market Size, by Country, 2017-2032 (USD Million)
TABLE 240. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, 2017-2032 (USD Million)
TABLE 241. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 242. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 243. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 244. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 245. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 246. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 247. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 248. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 249. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 250. United States Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 251. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, 2017-2032 (USD Million)
TABLE 252. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 253. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 254. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 255. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 256. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 257. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 258. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 259. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 261. Canada Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 262. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, 2017-2032 (USD Million)
TABLE 263. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 264. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 265. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 266. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 267. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 268. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 269. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 270. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 271. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 272. Mexico Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 273. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, 2017-2032 (USD Million)
TABLE 274. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 275. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 276. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 277. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 278. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 279. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 280. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 281. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 282. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 283. Brazil Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 284. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, 2017-2032 (USD Million)
TABLE 285. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 286. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 287. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 288. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 289. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 290. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 291. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 292. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 293. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 294. United Kingdom Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 295. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, 2017-2032 (USD Million)
TABLE 296. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 297. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 298. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 299. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 300. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 301. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 302. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 303. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 304. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 305. Germany Gamma-aminobutyric Acid Receptor Agonist Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 306. France Gamma-aminobutyric Acid Receptor Agonist Market Size, 2017-2032 (USD Million)
TABLE 307. France Gamma-aminobutyric Acid Receptor Agonist Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 308. France Gamma-aminobutyric Acid Receptor Agonist Market Size, by Barbiturate, 2017-2032 (USD Million)
TABLE 309. France Gamma-aminobutyric Acid Receptor Agonist Market Size, by Benzodiazepine, 2017-2032 (USD Million)
TABLE 310. France Gamma-aminobutyric Acid Receptor Agonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 311. France Gamma-aminobutyric Acid Receptor Agonist Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 312. France Gamma-aminobutyric Acid Receptor Agonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 313. France Gamma-aminobutyric Acid Receptor Agonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 314. France Gamma-aminobutyric Acid Receptor Agonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 315. France Gamma-a

Companies Mentioned

  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Hikma Pharmaceuticals PLC
  • Jazz Pharmaceuticals plc
  • Lupin Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Related Topics

Related Reports

Restless Legs Syndrome - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Restless Legs Syndrome - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Fragile X Syndrome (FXS) Treatment Market Report 2026 - Product Image

Fragile X Syndrome (FXS) Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Lower-Limb Spasticity - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Lower-Limb Spasticity - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
GLP-1 Receptor Agonist Market - Global Forecast 2026-2032 - Product Image

GLP-1 Receptor Agonist Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Insomnia Pharmacological Treatment Market - Global Forecast 2026-2032 - Product Image

Insomnia Pharmacological Treatment Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.